Medical Marijuana

by Kevin Mahmalji, NORML Outreach DirectorOctober 3, 2018 With 47 states and the District of Columbia permitting the use of marijuana or its extracts in some form, new questions concerning employers’ rights, lawful marijuana use by employees, and maintaining a...

Photo by Kristen Nichols (This is an abridged version of a story that appears in the September issue of Marijuana Business Magazine.) Talking about CBD in a nursing home? You’d better bring extra chairs and slices of cake for the overflow crowd....

The U.S. Food and Drug Administration noted that cannabidiol shouldn’t be a controlled substance, but international treaties require the United States to treat it as one.That revelation from the federal agency appeared in a 27-page memo written after it approved the first...

(This story has been updated with the USDA comment saying it will continue enforcing the current law.) The law that ushered in the modern hemp industry in the United States has expired, but hemp growers, processors and retailers are counting...

by Kevin Mahmalji, NORML Outreach DirectorSeptember 30, 2018 Everyday NORML Chapters from around the country invest countless hours in advocating for meaningful marijuana law reforms on the local, state and federal level! Below is a brief rundown of some of...

by Kevin Mahmalji, NORML Outreach DirectorSeptember 28, 2018 We as advocates of marijuana law reforms have never been in a better position than we are today to further our cause. Prior to states like Colorado, Washington, Oregon, Nevada, and others,...

Australian CBD company Elixinol Global raised 40 million Australian dollars ($29 million) in a new share placement to ramp up sales and marketing efforts in the United States and Europe. The capital raise comes less than a week after the...

In June of 2018, the FDA approved, for the first time, a cannabis based drug. Epidiolex, is a CBD drug used to treat Dravet Syndrome. Dravet Syndrome is a devastating form of lifelong epilepsy that reveals itself in infancy....

(This story has been updated to provide additional details from the DEA announcement.) The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic,...

by NORML September 27, 2018 Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The...